BioSpace News Archive

This patented superalloy has greater strength and scratch and fatigue resistance compared to titanium, cobalt and iron alloys.

Eric Cornut is rejoining the Helsinn Group Board, having previously held a Board role from May 2017 – October 2018.

Rockwell Medical, Inc. announced that it has entered into license and supply agreements with a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd., for the rights to commercialize Triferic in India.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-55.

Top-level, distance education laboratory curriculum from Science Interactive Group will be featured in Odigia online learning platform and digital resource library

Civica Rx (Civica, Inc.) today announced that it is interested in talking to generic drug manufacturers who are considering retiring or withdrawing their Abbreviated New Drug Applications (ANDAs) for essential medicines that are at risk of being in short supply

Therap’s Comprehensive Health Assessment Tool provides support and health professionals with a suite of health evaluation features in assessing individuals receiving nursing care.

ASC Therapeutics, a privately-held gene therapy company focused on developing transformative gene-based medicines for serious diseases, announced that it has entered into a long-term strategic manufacturing partnership with Vigene Biosciences, a Maryland-based Contract Develop and Manufacturing Organization.

Fourth quarter 2019 reported revenue is expected to be at or near the low end of the previously communicated guidance range of $395 to $400 million, representing organic revenue growth of slightly less than 5% and reported growth of approximately 3%;

Aptinyx Inc. announced the closing of its public offering of 11,691,666 shares of its common stock, which included the exercise in full of the underwriters’ option to purchase additional shares, at a public offering price of $3.00 per share.